The prior year Say on Pay vote received only 60.9% support, which is below the 70% threshold that normally requires visible changes or a No vote — however, the company conducted extensive shareholder outreach, meeting with investors representing approximately 50% of outstanding shares, and shareholders broadly confirmed support for the overall compensation structure and the multi-year Senior Executive Compensation Program, providing no specific go-forward modification requests. The compensation program is heavily weighted toward variable, performance-linked pay: the large equity awards for senior executives (performance stock awards with rigorous share price hurdles at $15–$30 per share) are directly tied to stock price milestones that shareholders have benefited from, with ROIV's share price rising approximately 175% during fiscal 2025 and all six performance tranches ultimately satisfying their price hurdles, demonstrating genuine pay-for-performance alignment. While the CEO reported in the compensation database is Eric Venker (total compensation $24.4 million, largely comprising Immunovant equity awards reflecting his dual role as Immunovant CEO), and the program's front-loaded, multi-year grant structure is complex and contributed to the prior low vote, the company's engagement response, the meaningful performance conditions on equity awards, the clawback policy, and the exceptional shareholder returns together justify a FOR determination despite the prior low support.

Non-audit fees (tax fees of $77,250 plus other fees of $7,839, totaling $85,089) represent approximately 2.7% of audit fees ($3,110,437), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so no tenure trigger fires per policy; EY is a Big 4 firm appropriate for a company of ROIV's $23.8 billion market cap; and no material financial restatements are noted.